Phathom Pharmaceuticals, Inc.
PHAT Healthcare Biotechnology
Phathom Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $175.1 million, up 216.9% from fiscal 2024. In the quarter to June 2026, revenue grew 88.0%, EPS grew 80.0%, free cash flow grew 96.9% and total debt fell 19.8%, each against the same quarter a year earlier.
Follow PHAT
Phathom Pharmaceuticals, Inc. (PHAT) P/E ratio
Phathom Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLYM Climb Bio, Inc. compare | n/m |
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. | n/m |
| SLDB Solid Biosciences Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | n/m |
| CRMD CorMedix Inc compare | 3.0× |
| ZVRA Zevra Therapeutics, Inc. compare | 10.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)